{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:00:00Z","timestamp":1768917600796,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe COPD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Double-blind, randomized, dose-finding trial with an eight-treatment, two-period, balanced incomplete block design. Patients (smoking history \u226510 pack-years, post-bronchodilator FEV<jats:sub>1<\/jats:sub> \u226530% and &lt;80% predicted, FEV<jats:sub>1<\/jats:sub>\/FVC &lt;0.7) were randomized to one of 16 independent sequences for 28\u2009days. Primary endpoint: mean trough FEV<jats:sub>1<\/jats:sub> at Day 28.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>385 patients (mean age 61.2\u2009years; mean post-bronchodilator FEV<jats:sub>1<\/jats:sub> 53% predicted) were randomized; 88.6% completed. All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV<jats:sub>1<\/jats:sub> versus placebo were statistically significant for all regimens, ranging from 51\u2009mL (glycopyrronium bromide 12.5\u2009\u03bcg OD) to 160\u2009mL (glycopyrronium bromide 50\u2009\u03bcg BID). Pharmacodynamic steady-state was reached by Day 7. There was a small separation (\u226437\u2009mL) between BID and OD dose\u2013response curves for mean trough FEV<jats:sub>1<\/jats:sub> at steady-state in favour of BID dosing. Over 24\u2009hours, separation between OD and BID regimens was even smaller (FEV<jats:sub>1<\/jats:sub> AUC<jats:sub>0-24h<\/jats:sub> maximum difference for equivalent daily dose regimens: 8\u2009mL). Dose\u2013response results for FEV<jats:sub>1<\/jats:sub> at 12\u2009hours, FEV<jats:sub>1<\/jats:sub> AUC<jats:sub>0-12h<\/jats:sub> and FEV<jats:sub>1<\/jats:sub> AUC<jats:sub>0-4h<\/jats:sub> at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25\u2009\u03bcg, 50\u2009\u03bcg and 100\u2009\u03bcg, while the reverse was true for OD versus BID regimens from 12\u201324\u2009hours. The 12.5\u2009\u03bcg BID dose produced a marginally higher improvement in trough FEV<jats:sub>1<\/jats:sub> versus placebo than 50\u2009\u03bcg OD, however, the response at 12\u2009hours over placebo was suboptimal (74\u2009mL). Glycopyrronium bromide was safe and well tolerated at all doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Glycopyrronium bromide 50\u2009\u03bcg OD provides significant bronchodilation over a 24\u2009hour period, and in terms of FEV<jats:sub>1<\/jats:sub> AUC<jats:sub>0-24h<\/jats:sub> is not significantly different than the same total daily dose administered BID. Importantly, OD dosing may confer better patient adherence. The results are consistent with previous glycopyrronium bromide studies and support once-daily dosing of glycopyrronium bromide 50\u2009\u03bcg in patients with moderate-to-severe COPD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov: NCT01119950<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2466-12-74","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T23:14:15Z","timestamp":1355008455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A novel model-based approach for dose determination of glycopyrronium bromide in COPD"],"prefix":"10.1186","volume":"12","author":[{"given":"Helen","family":"Arievich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Alagappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Looby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,8]]},"reference":[{"key":"360_CR1","unstructured":"Global initiative for chronic obstructive lung diseases (GOLD): Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. (http:\/\/www.goldcopd.com) 2010"},{"key":"360_CR2","volume-title":"The global burden of disease 2004 update","author":"World Health Organization (WHO)","year":"2008","unstructured":"World Health Organization (WHO): The global burden of disease 2004 update. 2008, Geneva, Switzerland: World Health Organization"},{"key":"360_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1183\/09031936.00127809","volume":"36","author":"T Troosters","year":"2010","unstructured":"Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M, UPLIFT Study Investigators: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010, 36: 65-73. 10.1183\/09031936.00127809.","journal-title":"Eur Respir J"},{"key":"360_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1753465811406001","volume":"5","author":"C Vogelmeier","year":"2011","unstructured":"Vogelmeier C, Banerji D: NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2011, 5: 163-173. 10.1177\/1753465811406001.","journal-title":"Ther Adv Respir Dis"},{"key":"360_CR5","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.rmed.2010.04.006","volume":"104","author":"C Verkindre","year":"2010","unstructured":"Verkindre C, Fukuchi Y, Fl\u00e9male A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010, 104: 1482-1489. 10.1016\/j.rmed.2010.04.006.","journal-title":"Respir Med"},{"key":"360_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1183\/09031936.00040712","volume":"40","author":"E Kerwin","year":"2012","unstructured":"Kerwin E, H\u00e9bert J, Gallagher N, Martin C, Overend T, Alagappan VKT, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52\u2009weeks: The GLOW2 study. Eur Respir J. 2012, 40: 1106-14. 10.1183\/09031936.00040712.","journal-title":"Eur Respir J"},{"key":"360_CR7","first-page":"A4422","volume":"181","author":"T Overend","year":"2010","unstructured":"Overend T, Lu Y, Dolker M, Banerji D: Dose response of NVA237, a long-acting muscarinic antagonist for the treatment of COPD. Am J Respir Crit Care Med. 2010, 181: A4422-","journal-title":"Am J Respir Crit Care Med"},{"key":"360_CR8","first-page":"334","volume":"105","author":"C Fogarty","year":"2010","unstructured":"Fogarty C, Hattersley H, Di Scala L, Drollmann A: Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010, 105: 334-342.","journal-title":"Respir Med"},{"key":"360_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.pupt.2010.04.005","volume":"23","author":"C Vogelmeier","year":"2010","unstructured":"Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, G\u00fc\u00e7l\u00fc SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK: Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010, 23: 438-444. 10.1016\/j.pupt.2010.04.005.","journal-title":"Pulm Pharmacol Ther"},{"key":"360_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1465-9921-12-54","volume":"12","author":"D Renard","year":"2011","unstructured":"Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR: Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011, 12: 54-10.1186\/1465-9921-12-54.","journal-title":"Respir Res"},{"key":"360_CR11","first-page":"167","volume":"1","author":"D Renard","year":"2011","unstructured":"Renard D, Stanski DR, Morris D, Looby M: Improving dose\u2013response assessments of bronchodilators, using indacaterol as an example. RDD Europe. 2011, 1: 167-176.","journal-title":"RDD Europe"},{"key":"360_CR12","volume-title":"Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD","author":"Global initiative for chronic obstructive lung diseases (GOLD)","year":"2008","unstructured":"Global initiative for chronic obstructive lung diseases (GOLD): Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2008, http:\/\/www.goldcopd.com,"},{"key":"360_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF: Minimal clinically important differences in COPD lung function. COPD. 2005, 2: 111-124. 10.1081\/COPD-200053377.","journal-title":"COPD"},{"key":"360_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1378\/chest.11-0406","volume":"141","author":"R Fuhr","year":"2012","unstructured":"Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten A-M, Falques M, Caracta CF, Gil EG: Efficacy of aclidinium bromide 400\u2009\u03bcg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012, 141: 745-752. 10.1378\/chest.11-0406.","journal-title":"Chest"},{"key":"360_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.201103-0405PP","volume":"184","author":"A Agusti","year":"2011","unstructured":"Agusti A, Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 184: 507-513. 10.1164\/rccm.201103-0405PP.","journal-title":"Am J Respir Crit Care Med"},{"key":"360_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/thx.2007.086041","volume":"63","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax. 2008, 63: 831-838. 10.1136\/thx.2007.086041.","journal-title":"Thorax"},{"key":"360_CR17","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001, 23: 1296-1310. 10.1016\/S0149-2918(01)80109-0.","journal-title":"Clin Ther"},{"key":"360_CR18","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.rmed.2007.01.025","volume":"101","author":"NS Breekveldt-Postma","year":"2007","unstructured":"Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM: Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007, 101: 1398-1405. 10.1016\/j.rmed.2007.01.025.","journal-title":"Respir Med"},{"key":"360_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1465-9921-11-149","volume":"11","author":"DP Tashkin","year":"2010","unstructured":"Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010, 11: 149-10.1186\/1465-9921-11-149.","journal-title":"Respir Res"},{"key":"360_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS: Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011, 105: 435-441. 10.1016\/j.rmed.2010.09.006.","journal-title":"Respir Med"},{"key":"360_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Yates BS, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356: 775-789. 10.1056\/NEJMoa063070.","journal-title":"N Engl J Med"},{"key":"360_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12325-010-0017-6","volume":"27","author":"KM Beeh","year":"2010","unstructured":"Beeh KM, Beier J: The short, the long and the \"ultra-long\": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther. 2010, 27: 150-159. 10.1007\/s12325-010-0017-6.","journal-title":"Adv Ther"},{"key":"360_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thx.2009.113662","volume":"64","author":"J Vestbo","year":"2009","unstructured":"Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009, 64: 939-943. 10.1136\/thx.2009.113662.","journal-title":"Thorax"},{"key":"360_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1164\/ajrccm.152.2.7633711","volume":"152","author":"CS Rand","year":"1995","unstructured":"Rand CS, Nides M, Cowles MK, Wise RA, Connett J: Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1995, 152: 580-588.","journal-title":"Am J Respir Crit Care Med"},{"key":"360_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/02770900009055445","volume":"37","author":"PM van Grunsven","year":"2000","unstructured":"van Grunsven PM, van Schayck CP, van Deuveren M, van Herwaarden CL, Akkermans RP, van Weel C: Compliance during long term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma. 2000, 37: 225-234. 10.3109\/02770900009055445.","journal-title":"J Asthma"},{"key":"360_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11096-008-9197-4","volume":"30","author":"D Haupt","year":"2008","unstructured":"Haupt D, Krigsman K, Nilsson JL: Medication persistence among patients with asthma\/COPD drugs. Pharm World Sci. 2008, 30: 509-514. 10.1007\/s11096-008-9197-4.","journal-title":"Pharm World Sci"},{"key":"360_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/pds.1321","volume":"16","author":"K Krigsman","year":"2007","unstructured":"Krigsman K, Nilsson JL, Ring L: Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf. 2007, 16: 441-448. 10.1002\/pds.1321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"360_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2710.2007.00866.x","volume":"32","author":"K Krigsman","year":"2007","unstructured":"Krigsman K, Moen J, Nilsson JL, Ring L: Refill adherence by the elderly for asthma\/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J Clin Pharm Ther. 2007, 32: 603-611. 10.1111\/j.1365-2710.2007.00866.x.","journal-title":"J Clin Pharm Ther"},{"key":"360_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1465-9921-12-156","volume":"12","author":"A D'Urzo","year":"2011","unstructured":"D'Urzo A, Ferguson G, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011, 12: 156-10.1186\/1465-9921-12-156.","journal-title":"Respir Res"},{"key":"360_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/COPD.S32451","volume":"7","author":"KM Beeh","year":"2012","unstructured":"Beeh KM, Singh D, Di Scala L, Drollmann A: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD. 2012, 7: 503-513.","journal-title":"Int J COPD"},{"key":"360_CR31","first-page":"A2254","volume":"185","author":"PE Korenblat","year":"2012","unstructured":"Korenblat PE, Hebert J, Gallagher N, Martin C, Banerji D, Lu Y: NVA237 once daily improves dyspnea and health-related quality of life in patients with COPD: the GLOW2 trial. Am J Respir Crit Care Med. 2012, 185: A2254-","journal-title":"Am J Respir Crit Care Med"},{"key":"360_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5414\/CP201612","volume":"50","author":"R Sechaud","year":"2012","unstructured":"Sechaud R, Renard D, Zhang-Auberson L, de la Motte S, Drollmann A, Kaiser G: The pharmacokinetics of multiple inhaled NVA237 doses at four dose levels in COPD patients. Int J Clin Pharmacol Ther. 2012, 50: 118-128.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"360_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1465-9921-12-40","volume":"12","author":"M Westwood","year":"2011","unstructured":"Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011, 12: 40-10.1186\/1465-9921-12-40.","journal-title":"Respir Res"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-12-74.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-12-74\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-12-74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-12-74.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:49:01Z","timestamp":1630529341000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-12-74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-12-74","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"23 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"74"}}